Skip to main content
SpringerLink
Log in

Anti-Idiotype Antibodies

  • Reference work entry
  • First Online:
Cancer Therapeutic Targets

  • 1890 Accesses

Abstract

The tumor-specific immunoglobulin (Ig) expressed by B-cell malignancies can serve as a target for passive or active immunotherapy. This target, referred to as the “idiotype” (Id), is composed of the unique antigenic determinants in the variable regions of the clonal Ig heavy and light chains expressed by the tumor cells (Timmerman and Levy, Clin Lymphoma 1:129–139, 2000). This protein target has the unusual nature of being unique in every B-cell cancer (Fig. 1). The human immune system contains billions of different B cells, each with a unique Ig polypeptide sequence resulting from the physiologic rearrangement and somatic mutation of gene segments during B-cell differentiation. The Ig is expressed on the B-cell surface to serve as an antigen receptor (B-cell receptor, BCR).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 649.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 949.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Abdalla AO, Hansson L, Eriksson I, Nasman-Glaser B, Mellstedt H, Osterborg A. Long-term effects of idiotype vaccination on the specific T-cell response in peripheral blood and bone marrow of multiple myeloma patients. Eur J Haematol. 2007a;79(5):371–81.

    Article  CAS  PubMed  Google Scholar 

  • Abdalla AO, Hansson L, Eriksson I, et al. Idiotype protein vaccination in combination with adjuvant cytokines in patients with multiple myeloma – evaluation of T-cell responses by different read-out systems. Haematologica. 2007b;92(1):110–4.

    Article  CAS  PubMed  Google Scholar 

  • Abdalla AO, Kokhaei P, Hansson L, Mellstedt H, Osterborg A. Idiotype vaccination in patients with myeloma reduced circulating myeloma cells (CMC). Ann Oncol. 2008;19(6):1172–9.

    Article  CAS  PubMed  Google Scholar 

  • Barrios Y, Cabrera R, Yanez R, et al. Anti-idiotypic vaccination in the treatment of low-grade B-cell lymphoma. Haematologica. 2002;87(4):400–7.

    PubMed  Google Scholar 

  • Bendandi M, Gocke CD, Kobrin CB, et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma [see comments]. Nat Med. 1999;5(10):1171–7.

    Article  CAS  PubMed  Google Scholar 

  • Bertinetti C, Simon F, Zirlik K, et al. Cloning of idiotype immunoglobulin genes in B cell lymphomas by anchored PCR and production of individual recombinant idiotype vaccines in Escherichia coli. Eur J Haematol. 2006a;77(5):395–402.

    Article  CAS  PubMed  Google Scholar 

  • Bertinetti C, Zirlik K, Heining-Mikesch K, et al. Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression. Cancer Res. 2006b;66(8):4496–502.

    Article  CAS  PubMed  Google Scholar 

  • Betting DJ, Kafi K, Abdollahi-Fard A, Hurvitz SA, Timmerman JM. Sulfhydryl-based tumor antigen-carrier protein conjugates stimulate superior anti-tumor immunity against B cell lymphomas. J Immunol. 2008;181:4131–40.

    Article  CAS  PubMed  Google Scholar 

  • Bogen B, Ruffini PA, Corthay A, et al. Idiotype-specific immunotherapy in multiple myeloma: suggestions for future directions of research. Haematologica. 2006;91(7):941–8.

    CAS  PubMed  Google Scholar 

  • Carey GB, Donjerkovic D, Mueller CM, et al. B-cell receptor and Fas-mediated signals for life and death. Immunol Rev. 2000;176:105–15.

    Article  CAS  PubMed  Google Scholar 

  • Davis TA, Maloney DG, Czerwinski DK, Liles TM, Levy R. Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin’s lymphoma without eradicating the malignant clone. Blood. 1998;92(4):1184–90.

    CAS  PubMed  Google Scholar 

  • Eeva J, Pelkonen J. Mechanisms of B cell receptor induced apoptosis. Apoptosis. 2004;9(5):525–31.

    Article  CAS  PubMed  Google Scholar 

  • Freedman A, Neelapu SS, Nichols C, et al. Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma. J Clin Oncol. 2009;27(18):3036–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hall SS. Dr. Levy’s favorite guinea pig, A commotion in the blood. New York: Henry Holt & Company; 1997. p. 391–408.

    Google Scholar 

  • Hansson L, Rabbani H, Fagerberg J, Osterborg A, Mellstedt H. T-cell epitopes within the complementarity-determining and framework regions of the tumor-derived immunoglobulin heavy chain in multiple myeloma. Blood. 2003;101(12):4930–6.

    Article  CAS  PubMed  Google Scholar 

  • Hansson L, Abdalla AO, Moshfegh A, et al. Long-term idiotype vaccination combined with interleukin-12 (IL-12), or IL-12 and granulocyte macrophage colony-stimulating factor, in early-stage multiple myeloma patients. Clin Cancer Res. 2007;13(5):1503–10.

    Article  CAS  PubMed  Google Scholar 

  • Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med. 1996;2(1):52–8.

    Article  CAS  PubMed  Google Scholar 

  • Hsu FJ, Caspar CB, Czerwinski D, et al. Tumor-specific idiotype vaccines in the treatment of patients with B- cell lymphoma – long-term results of a clinical trial. Blood. 1997;89(9):3129–35.

    CAS  PubMed  Google Scholar 

  • Inoges S, Rodriguez-Calvillo M, Zabalegui N, et al. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J Natl Cancer Inst. 2006;98(18):1292–301.

    Article  PubMed  Google Scholar 

  • Kafi K, Betting DJ, Yamada RE, Bacica M, Steward KK, Timmerman JM. Maleimide conjugation markedly enhances the immunogenicity of both human and murine idiotype-KLH vaccines. Mol Immunol. 2009;46(3):448–56.

    Article  CAS  PubMed  Google Scholar 

  • Kanter G, Yang J, Voloshin A, Levy S, Swartz JR, Levy R. Cell-free production of scFv fusion proteins: an efficient approach for personalized lymphoma vaccines. Blood. 2007;109(8):3393–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kim SB, Baskar S, Kwak LW. In vitro priming of myeloma antigen-specific allogeneic donor T cells with idiotype pulsed dendritic cells. Leuk Lymphoma. 2003;44(7):1201–8.

    Article  CAS  PubMed  Google Scholar 

  • Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med. 1992;327(17):1209–15.

    Article  CAS  PubMed  Google Scholar 

  • Kwak LW, Young HA, Pennington RW, Weeks SD. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc Natl Acad Sci U S A. 1996;93(20):10972–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Levy R, Dilley J. Rescue of immunoglobulin secretion from human neoplastic lymphoid cells by somatic cell hybridization. Proc Natl Acad Sci U S A. 1978;75(5):2411–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Levy R, Robertson MJ, Ganjoo K, Leonard JP, Vose J, Denney D. Results of a phase 3 trial evaluating safety and efficacy of specific immunotherapy, recombinant idiotype (Id) conjugated to KLH (Id-KLH) with GM-CSF, compared to non-specific immunotherapy, KLH with GM-CSF, in patients with follicular non-Hodgkin’s lymphoma (fNHL). Proceedings of the 99th Annual Meeting of the American Association for Cancer Research; 12–16 Apr 2008; San Diego, CA Philadelphia (PA): AACR; 2008 Abstract LB-204 2008.

    Google Scholar 

  • Li Y, Bendandi M, Deng Y, et al. Tumor-specific recognition of human myeloma cells by idiotype-induced CD8(+) T cells. Blood. 2000;96(8):2828–33.

    CAS  PubMed  Google Scholar 

  • Lynch RG, Graff RJ, Sirisinha S, Simms ES, Eisen HN. Myeloma proteins as tumor-specific transplantation antigens. Proc Natl Acad Sci U S A. 1972;69(6):1540–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Maloney DG, Brown S, Czerwinski DK, et al. Monoclonal anti-idiotype antibody therapy of B-cell lymphoma: the addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype-negative variant cells. Blood. 1992;80(6):1502–10.

    CAS  PubMed  Google Scholar 

  • McCormick AA, Kumagai MH, Hanley K, et al. Rapid production of specific vaccines for lymphoma by expression of the tumor-derived single-chain Fv epitopes in tobacco plants. Proc Natl Acad Sci U S A. 1999;96(2):703–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Meeker T, Lowder J, Cleary ML, et al. Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies. N Engl J Med. 1985;312(26):1658–65.

    Article  CAS  PubMed  Google Scholar 

  • Miller RA, Maloney DG, Warnke R, Levy R. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med. 1982;306(9):517–22.

    Article  CAS  PubMed  Google Scholar 

  • Miller RA, Hart S, Samoszuk M, et al. Shared idiotypes expressed by human B-cell lymphomas. N Engl J Med. 1989;321(13):851–7.

    Article  CAS  PubMed  Google Scholar 

  • Niiro H, Maeda A, Kurosaki T, Clark EA. The B lymphocyte adaptor molecule of 32 kD (Bam32) regulates B cell antigen receptor signaling and cell survival. J Exp Med. 2002;195(1):143–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Rasmussen T, Hansson L, Osterborg A, Johnsen HE, Mellstedt H. Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells. Blood. 2003;101(11):4607–10.

    Article  CAS  PubMed  Google Scholar 

  • Redfern CH, Guthrie TH, Bessudo A, et al. Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin’s lymphoma resulting in durable clinical responses. J Clin Oncol. 2006;24(19):3107–12.

    Article  CAS  PubMed  Google Scholar 

  • Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83(2):435–45.

    CAS  PubMed  Google Scholar 

  • Reichardt VL, Okada CY, Stockerl-Goldstein KE, Bogen B, Levy R. Rationale for adjuvant idiotypic vaccination after high-dose therapy for multiple myeloma. Biol Blood Marrow Transplant. 1997;3(3):157–63 [9310193].

    CAS  PubMed  Google Scholar 

  • Reichardt VL, Okada CY, Liso A, et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma – a feasibility study. Blood. 1999;93(7):2411–9.

    CAS  PubMed  Google Scholar 

  • Reitan SK, Hannestad K. Immunoglobulin heavy chain constant regions regulate immunity and tolerance to idiotypes of antibody variable regions. Proc Natl Acad Sci U S A. 2002;99(11):7588–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Schuster SJ, Neelapu SS, Gause BL, et al. Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: phase III clinical trial results. J Clin Oncol. 2009;27(suppl; abstr 2):15s. ASCO Plenary Session, May 31, 2009.

    Google Scholar 

  • Schuster SJ, Santos CF, Neelapu SS, et al. Vaccination with IgM but not IgG idiotype prolongs remission duration in follicular lymphoma patients. Blood. 2010;American Society of Hematology Annual Meeting Abstracts, 116: Abstract 429.

    Google Scholar 

  • Stevenson FK, Elliott EV, Stevenson GT. Some effects on leukaemic B lymphocytes of antibodies to defined regions of their surface immunoglobulin. Immunology. 1977;32(4):549–57.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Timmerman JM. Therapeutic idiotype vaccines for non-Hodgkin’s lymphoma. Adv Pharmacol. 2004;51:271–93.

    Article  CAS  PubMed  Google Scholar 

  • Timmerman JM, Levy RL. The history of the development of vaccines for lymphoma. Clin Lymphoma. 2000;1:129–39.

    Article  CAS  PubMed  Google Scholar 

  • Timmerman JM, Czerwinski DK, Davis TA, et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood. 2002;99(5):1517–26.

    Article  CAS  PubMed  Google Scholar 

  • Timmerman JM, Vose JM, Czerwinski DK, et al. Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma. Leuk Lymphoma. 2009;50(1):37–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Varghese B, Widman A, Do J, et al. Generation of CD8+ T cell-mediated immunity against idiotype-negative lymphoma escapees. Blood. 2009;114:4477–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Vuist WM, Levy R, Maloney DG. Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor expression of high levels of bcl-2 protein. Blood. 1994;83(4):899–906.

    CAS  PubMed  Google Scholar 

  • Weng WK, Czerwinski D, Timmerman J, Hsu FJ, Levy R. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J Clin Oncol. 2004;22(23):4717–24.

    Article  CAS  PubMed  Google Scholar 

  • Weng J, Neelapu SS, Woo AF, Kwak LW. Identification of human idiotype-specific T cells in lymphoma and myeloma. Curr Top Microbiol Immunol. 2011;344:193–210.

    CAS  PubMed  Google Scholar 

  • Yanez R, Barrios Y, Ruiz E, Cabrera R, Diaz-Espada F. Anti-idiotypic immunotherapy in follicular lymphoma patients: results of a long follow-up study. J Immunother. 2008;31(3):310–2.

    Article  PubMed  Google Scholar 

  • Yi Q, Szmania S, Freeman J, et al. Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients. Br J Haematol. 2010;150(5):554–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Health Sciences 42-121, UCLA Lymphoma Program, Division of Hematology and Oncology, University of California at Los Angeles, 10833 LeConte Avenue, Los Angeles, CA, 90095-1678, USA

    John M. Timmerman

Authors
  1. John M. Timmerman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John M. Timmerman .

Editor information

Editors and Affiliations

  1. Division of Hematology & Oncology, Georgetown Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, USA

    John L. Marshall

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer Science+Business Media New York

About this entry

Cite this entry

Timmerman, J.M. (2017). Anti-Idiotype Antibodies. In: Marshall, J. (eds) Cancer Therapeutic Targets. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-0717-2_51

Download citation

Publish with us

Policies and ethics

Search

Navigation